Cell therapy practices date back to the 19th century and continue to expand on
investigational and investment grounds. Cell therapy includes stem cell-and non–stem cell …

Bispecific T cell engagers (BiTEs) are an innovative class of immunotherapeutics that
redirect T cells to tumor surface antigens. While efficacious against certain hematological …

The strategy of using mesenchymal stem cells (MSCs) as a living carrier for active delivery of
therapeutic agents targeting tumor sites has been attempted in a wide range of studies to …

Malignant brain tumors constitute nearly one-third of cancer diagnoses in children and have
recently surpassed hematologic malignancies as the most lethal neoplasm in the pediatric …

Osteosarcoma (OS) is an aggressive bone tumor that mainly affects children and
adolescents. OS has a strong tendency to relapse and metastasize, resulting in poor …

Oncolytic viruses (OVs) infect, multiply, and finally remove tumor cells selectively, causing no
damage to normal cells in the process. Because of their specific features, such as, the ability …

Purpose: Diffuse intrinsic pontine glioma (DIPG) is among the deadliest of pediatric brain
tumors. Radiotherapy is the standard-of-care treatment for DIPG, but offers only transient …

It has been intensively reported that the immunosuppressive tumor microenvironment (TME)
results in tumor resistance to immunotherapy, especially immune checkpoint blockade and …

Introduction Drug delivery to solid tumors remains a significant therapeutic challenge.
Mesenchymal stem/stromal cells (MSCs) home to tumor tissues and can be employed as …

Introduction Mesenchymal stromal cell (MSC)-based therapy has generated great hope for
the treatment of various diseases such as myocardial infarction and stroke. Unfortunately …